Deenova Triples its 2020 Unprecedented Winning Streak in France’s Pharmacy Automation Market
Deenova publicly disclosed that its ongoing market success in 2020 relentlessly continues in France, with new business contracts won by Deenova for tenders awarded by GHICL, Resah, Achat Hopital, Saint-Brieuc Hospital Center, and Argenteuil Hospital Center for multiple unit-dose robots, and separately a business contract with UniHA for the use of Deenova’s world-class traceability solutions for medical devices and medications throughout France.
Gaspar G. De Viedma, Vice Chairman of Deenova´s Board of Directors stated: “I can speak for all Board members continued satisfaction with our 2020 commercial progress, especially in these difficult Covid-19 times, and to combine new business contracts at premier hospitals in France and Spain, with additional purchases by previous Deenova customers, clearly showing a high level of continued satisfaction with our automation solutions amongst our existing customer base.”
Supported by the Catholic Institute of Lille, GHICL is a private, nonprofit university hospital group that manages 686 beds across two facilities, with comprehensive care services that include emergency, surgery, pharmacy, adult psychiatry, obstetrics, paediatric, rehabilitation, and units such as laboratories and surgeries.
The Saint-Brieuc Hospital Center is today the premier benchmark center for health region no. 7 in Brittany, providing specialized care for the entire department of Côtes d'Armor. With 1,238 beds, it serves a population of around 100,000 inhabitants.
The Argenteuil Hospital Center also plays a key role as a local hospital in a living area of nearly 300,000 inhabitants, with nearly 2,300 healthcare professionals located in Paris.
Resah is a public interest group (GIP) whose objective is to support the pooling and professionalisation of purchases from the health sector, public and private non-profit. It was created in 2007 to support the pooling of hospital purchases for the Ile-de-France region, in collaboration with Achat Hopital.
UniHA, the Union of Hospitals for Purchasing, is a cooperative of French public hospital buyers. Created in 2005 by the hospital staff themselves (32 CHU and 20 CH), today in 2020, 955 hospitals have joined the cooperative, 102 GHT and will have conducted € 4.6 billion in group purchases in 2019.
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Please visit www.deenova.com for additional information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005383/en/
Contact information
Contacts at Deenova:
Christophe Jaffuel, Elisa Mariotti
e.mariotti@deenova.com, +39 0523 785311
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 03:15:00 EET | Press release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 23:10:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerstone of IonQ’s global strategy,” said Niccolo de Masi, Chairman and CEO of IonQ. “QuantumBasel continues to be a critical innovation node for our company as
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 22:50:00 EET | Press release
Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s
SES Acknowledges Moody’s Rating Action and Reiterates Deleveraging Commitments17.12.2025 22:36:00 EET | Press release
SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Moody’s Investor Service today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. Consistent with this plan, it remains management’s intention to de-lever and return to credit metrics that are commensurate with investment grade, with a policy objective of reducing adjusted net leverage1 to at least 3.0x or below. Today’s rating action does not change the Company’s ability to operate its business, serve customers, or execute its strategic plan. SES maintains a balanced weighted average debt maturity profile of approximately five years, and the rating action from Moody’s is not expected to have a material impact on the interest payable under the Company’s existing debt facilities. SES also ben
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom